4,4'-(Carbonylbis(azanediyl))bis(N-(4-methylpyrimidin-2-yl)benzenesulfonamide) | 13616-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-(Carbonylbis(azanediyl))bis(N-(4-methylpyrimidin-2-yl)benzenesulfonamide)
• 英文别名: 1,3-bis[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]urea
• CAS: 13616-29-0
• 化学式: C₂₃H₂₂N₈O₅S₂
• 分子量: 554.6
• InChiKey: RSINKZJTTORDAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  202
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer
  申请人：3-V Biosciences, Inc.

  公开号：US10363249B2

  公开（公告）日：2019-07-30

  Compounds that are fatty acid synthesis modulators are provided. The compounds may be used in pharmaceutical compositions to treat taxane-resistant cancers. Methods are provided for treating taxane-resistant cancer in a subject. Methods are also provided for increasing the sensitivity of a cancer cell to taxanes (i.e., paclitaxel, Nab-paclitaxel docetaxel, and/or cabazitaxel) treatment.

  本研究提供了脂肪酸合成调节剂化合物。这些化合物可用于治疗抗类固醇癌症的药物组合物中。本发明提供了治疗受试者的抗类固醇癌症的方法。还提供了提高癌细胞对紫杉类药物（即紫杉醇、Nab-紫杉醇、多西他赛和/或卡巴他赛）治疗敏感性的方法。
• Means and methods for treatment of early-onset Parkinson's disease
  申请人：VIB VZW

  公开号：US11202795B2

  公开（公告）日：2021-12-21

  This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.

  本申请涉及神经退行性疾病领域，尤其是帕金森病领域。特别是，该公开内容描述了降低 FAS 活性的抑制剂可用于治疗帕金森病，尤其是治疗 PINK1 或 PARKIN 基因发生功能缺失突变的帕金森病患者。
• FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER
  申请人：Sagimet Biosciences Inc.

  公开号：EP3179990B1

  公开（公告）日：2020-10-14
• MEANS AND METHODS FOR TREATMENT OF EARLY-ONSET PARKINSON'S DISEASE
  申请人：VIB VZW

  公开号：US20170319610A1

  公开（公告）日：2017-11-09

  This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
• METHODS FOR TREATING CARDIAC VALVE DISEASE
  申请人：THEODORIS Christina

  公开号：US20210228594A1

  公开（公告）日：2021-07-29

  The present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.